Article Text

Research and guideline update
Mortality reduction in adult community-acquired pneumonia in the UK (2009–2014): results from the British Thoracic Society audit programme
  1. Priya Daniel1,
  2. Mark Woodhead2,
  3. Sally Welham3,
  4. Tricia M Mckeever4,
  5. Wei Shen Lim1
  6. on behalf of the British Thoracic Society
  1. 1Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK
  2. 2Department of Respiratory Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
  3. 3British Thoracic Society, London, UK
  4. 4Division of Epidemiology, University of Nottingham, Nottingham, UK
  1. Correspondence to Dr Priya Daniel, Department of Respiratory Medicine, David Evans Building, City Hospital Campus, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham NG5 1PB, UK; priyasosha.daniel{at}


Community-acquired pneumonia (CAP) is a leading cause of death in the UK. In this analysis of 23 315 cases from the British Thoracic Society national CAP audit, an overall reduction in 30-day inpatient mortality over 6 years was observed—2014 compared with 2009 adjusted OR 0.86 (95% CI 0.68 to 1.08, p for trend 0.004). Significant increases in the proportions of patients who had (a) a chest X-ray and (b) the first antibiotic dose within 4 hours of admission were also observed (3.7% and 11.5% increases respectively). Further reductions in mortality may follow the 2016 National Institute for Health and Care Excellence Pneumonia Quality Standard.

  • Pneumonia
  • Respiratory Infection
  • Clinical Epidemiology

Statistics from


  • Contributors WSL and SW were instrumental in organising the BTS national CAP audit; PD and TMM analysed and interpreted the data and drafted the article; TMM provided statistical input; TMM, MW, SW and WSL critically evaluated the article; all authors revised and reviewed the article prior to final approval.

  • Competing interests All authors have completed the International Committee of Medical Journal Editors uniform disclosure form. PD has received salaries funded by an unrestricted grant from Pfizer. WSL has received unrestricted investigator-initiated research funding from Pfizer for unrelated research in pneumonia. MW reports speaking at National and International Scientific meetings which were supported by multiple pharmaceutical companies but without personally receiving direct funding from any individual pharmaceutical companies.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles